Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Greg P. Boivin is active.

Publication


Featured researches published by Greg P. Boivin.


Circulation Research | 1999

Mouse Model of a Familial Hypertrophic Cardiomyopathy Mutation in α-Tropomyosin Manifests Cardiac Dysfunction

Mariappan Muthuchamy; Kathy Pieples; Prabhakar Rethinasamy; Brian D. Hoit; Ingrid L. Grupp; Greg P. Boivin; Beata M. Wolska; Christian C. Evans; R. John Solaro; David F. Wieczorek

To investigate the functional consequences of a tropomyosin (TM) mutation associated with familial hypertrophic cardiomyopathy (FHC), we generated transgenic mice that express mutant alpha-TM in the adult heart. The missense mutation, which results in the substitution of asparagine for aspartic acid at amino acid position 175, occurs in a troponin T binding region of TM. S1 nuclease mapping and Western blot analyses demonstrate that increased expression of the alpha-TM 175 transgene in different lines causes a concomitant decrease in levels of endogenous alpha-TM mRNA and protein expression. In vivo physiological analyses show a severe impairment of both contractility and relaxation in hearts of the FHC mice, with a significant change in left ventricular fractional shortening. Myofilaments that contain alpha-TM 175 demonstrate an increased activation of the thin filament through enhanced Ca2+ sensitivity of steady-state force. Histological analyses show patchy areas of mild ventricular myocyte disorganization and hypertrophy, with occasional thrombi formation in the left atria. Thus, the FHC alpha-TM transgenic mouse can serve as a model system for the examination of pathological and physiological alterations imparted through aberrant TM isoforms.


Circulation Research | 1998

Molecular and Physiological Effects of α-Tropomyosin Ablation in the Mouse

Prabhakar Rethinasamy; Mariappan Muthuchamy; Timothy E. Hewett; Greg P. Boivin; Beata M. Wolska; Christian C. Evans; R. John Solaro; David F. Wieczorek

Abstract —Tropomyosin (TM) is an integral component of the thin filament in muscle fibers and is involved in regulating actin-myosin interactions. TM is encoded by a family of four alternatively spliced genes that display highly conserved nucleotide and amino acid sequences. To assess the functional and developmental significance of α-TM, the murine α-TM gene was disrupted by homologous recombination. Homozygous α-TM null mice are embryonic lethal, dying between 8 and 11.5 days post coitum. Mice that are heterozygous for α-TM are viable and reproduce normally. Heterozygous knockout mouse hearts show a 50% reduction in cardiac muscle α-TM mRNA, with no compensatory increase in transcript levels by striated muscle β-TM or TM-30 isoforms. Surprisingly, this reduction in α-TM mRNA levels in heterozygous mice is not reflected at the protein level, where normal amounts of striated muscle α-TM protein are produced and integrated in the myofibril. Quantification of α-TM mRNA bound in polysomal fractions reveals that both wild-type and heterozygous knockout animals have similar levels. These data suggest that a change in steady-state level of α-TM mRNA does not affect the relative amount of mRNA translated and amount of protein synthesized. Physiological analyses of myocardial and myofilament function show no differences between heterozygous α-TM mice and control mice. The present study suggests that translational regulation plays a major role in the control of TM expression.


Circulation Research | 2007

Dilated Cardiomyopathy Mutant Tropomyosin Mice Develop Cardiac Dysfunction With Significantly Decreased Fractional Shortening and Myofilament Calcium Sensitivity

Sudarsan Rajan; Rafeeq P.H. Ahmed; Ganapathy Jagatheesan; Natalia Petrashevskaya; Greg P. Boivin; Dalia Urboniene; Grace M. Arteaga; Beata M. Wolska; R. John Solaro; Stephen B. Liggett; David F. Wieczorek

Mutations in striated muscle &agr;-tropomyosin (&agr;-TM), an essential thin filament protein, cause both dilated cardiomyopathy (DCM) and familial hypertrophic cardiomyopathy. Two distinct point mutations within &agr;-tropomyosin are associated with the development of DCM in humans: Glu40Lys and Glu54Lys. To investigate the functional consequences of &agr;-TM mutations associated with DCM, we generated transgenic mice that express mutant &agr;-TM (Glu54Lys) in the adult heart. Results showed that an increase in transgenic protein expression led to a reciprocal decrease in endogenous &agr;-TM levels, with total myofilament TM protein levels remaining unaltered. Histological and morphological analyses revealed development of DCM with progression to heart failure and frequently death by 6 months. Echocardiographic analyses confirmed the dilated phenotype of the heart with a significant decrease in the left ventricular fractional shortening. Work-performing heart analyses showed significantly impaired systolic, and diastolic functions and the force measurements of cardiac myofibers revealed that the myofilaments had significantly decreased Ca2+ sensitivity and tension generation. Real-time RT-PCR quantification demonstrated an increased expression of &bgr;-myosin heavy chain, brain natriuretic peptide, and skeletal actin and a decreased expression of the Ca2+ handling proteins sarcoplasmic reticulum Ca2+-ATPase and ryanodine receptor. Furthermore, our study also indicates that the &agr;-TM54 mutation decreases tropomyosin flexibility, which may influence actin binding and myofilament Ca2+ sensitivity. The pathological and physiological phenotypes exhibited by these mice are consistent with those seen in human DCM and heart failure. As such, this is the first mouse model in which a mutation in a sarcomeric thin filament protein, specifically TM, leads to DCM.


Circulation | 2010

Molecular and Functional Characterization of a Novel Cardiac-Specific Human Tropomyosin Isoform

Sudarsan Rajan; Ganapathy Jagatheesan; Chehade N. Karam; Marco S.L. Alves; Ilona Bodi; Arnold M. Schwartz; Christian F. Bulcao; Karen M. D'Souza; Shahab A. Akhter; Greg P. Boivin; Dipak K. Dube; Natalia Petrashevskaya; Andrew B. Herr; Roger Hullin; Stephen B. Liggett; Beata M. Wolska; R. John Solaro; David F. Wieczorek

Background— Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1&agr; (also called &agr;-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. Methods and Results— In this study, we quantified for the first time the levels of striated muscle TM isoforms in human heart, including a novel isoform called TPM1&kgr;. By developing a TPM1&kgr;-specific antibody, we found that the TPM1&kgr; protein is expressed and incorporated into organized myofibrils in hearts and that its level is increased in human dilated cardiomyopathy and heart failure. To investigate the role of TPM1&kgr; in sarcomeric function, we generated transgenic mice overexpressing cardiac-specific TPM1&kgr;. Incorporation of increased levels of TPM1&kgr; protein in myofilaments leads to dilated cardiomyopathy. Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunction, and decreased myofilament calcium sensitivity with no change in maximum developed tension. Additional biophysical studies demonstrate less structural stability and weaker actin-binding affinity of TPM1&kgr; compared with TPM1&agr;. Conclusions— This functional analysis of TPM1&kgr; provides a possible mechanism for the consequences of the TM isoform switch observed in dilated cardiomyopathy and heart failure patients.


Journal of Muscle Research and Cell Motility | 2010

Striated muscle tropomyosin isoforms differentially regulate cardiac performance and myofilament calcium sensitivity

Ganapathy Jagatheesan; Sudarsan Rajan; Rafeeq P.H. Ahmed; Natalia Petrashevskaya; Greg P. Boivin; Grace M. Arteaga; Hyun Jin Tae; Stephen B. Liggett; R. John Solaro; David F. Wieczorek

Tropomyosin (TM) plays a central role in calcium mediated striated muscle contraction. There are three muscle TM isoforms: α-TM, β-TM, and γ-TM. α-TM is the predominant cardiac and skeletal muscle isoform. β-TM is expressed in skeletal and embryonic cardiac muscle. γ-TM is expressed in slow-twitch musculature, but is not found in the heart. Our previous work established that muscle TM isoforms confer different physiological properties to the cardiac sarcomere. To determine whether one of these isoforms is dominant in dictating its functional properties, we generated single and double transgenic mice expressing β-TM and/or γ-TM in the heart, in addition to the endogenously expressed α-TM. Results show significant TM protein expression in the βγ-DTG hearts: α-TM: 36%, β-TM: 32%, and γ-TM: 32%. These βγ-DTG mice do not develop pathological abnormalities; however, they exhibit a hyper contractile phenotype with decreased myofilament calcium sensitivity, similar to γ-TM transgenic hearts. Biophysical studies indicate that γ-TM is more rigid than either α-TM or β-TM. This is the first report showing that with approximately equivalent levels of expression within the same tissue, there is a functional dominance of γ-TM over α-TM or β-TM in regulating physiological performance of the striated muscle sarcomere. In addition to the effect expression of γ-TM has on Ca2+ activation of the cardiac myofilaments, our data demonstrates an effect on cooperative activation of the thin filament by strongly bound rigor cross-bridges. This is significant in relation to current ideas on the control mechanism of the steep relation between Ca2+ and tension.


Journal of Molecular and Cellular Cardiology | 2001

A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice

Rethinasamy Prabhakar; Greg P. Boivin; Ingrid L. Grupp; Brian D. Hoit; Grace M. Arteaga; John R. Solaro; David F. Wieczorek


American Journal of Physiology-heart and Circulatory Physiology | 2007

Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis

Ganapathy Jagatheesan; Sudarsan Rajan; Natalia Petrashevskaya; Arnold Schwartz; Greg P. Boivin; Grace M. Arteaga; R. John Solaro; Stephen B. Liggett; David F. Wieczorek


American Journal of Physiology-heart and Circulatory Physiology | 2002

Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca2+ activation

Kathy Pieples; Grace Arteaga; R. John Solaro; Ingrid L. Grupp; John N. Lorenz; Greg P. Boivin; Ganapathy Jagatheesan; Erin Labitzke; Pieter Detombe; John P. Konhilas; Thomas C. Irving; David F. Wieczorek


Journal of Biological Chemistry | 2003

Functional Importance of the Carboxyl-terminal Region of Striated Muscle Tropomyosin

Ganapathy Jagatheesan; Sudarsan Rajan; Natalia Petrashevskaya; Arnold Schwartz; Greg P. Boivin; Susan Vahebi; Pieter Detombe; R. John Solaro; Erin Labitzke; George M. Hilliard; David F. Wieczorek


American Journal of Physiology-heart and Circulatory Physiology | 2004

Physiological significance of troponin T binding domains in striated muscle tropomyosin

Ganapathy Jagatheesan; Sudarsan Rajan; Natalia Petrashevskaya; Arnold Schwartz; Greg P. Boivin; Grace M. Arteaga; Pieter P. de Tombe; R. John Solaro; David F. Wieczorek

Collaboration


Dive into the Greg P. Boivin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

R. John Solaro

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sudarsan Rajan

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar

Stephen B. Liggett

University of South Florida

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Beata M. Wolska

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Ingrid L. Grupp

University of Cincinnati Academic Health Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge